Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost issues in sequential therapy

J Cooke1

  • 1Department of Pharmacy, South Manchester University Hospitals NHS Trust, UK.

The Journal of Infection
|November 20, 1998
PubMed
Summary
This summary is machine-generated.

Pharmacoeconomics guides antimicrobial decisions by analyzing costs beyond acquisition. Realizing potential savings requires addressing staff time, monitoring, and the significant impact of antimicrobial resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial.

EClinicalMedicine·2026
Same author

Next-generation precision medicine for suicidality prevention.

Translational psychiatry·2024
Same author

Circulating Angiogenic and Senescent T Lymphocytes in Ageing and Frailty.

The Journal of frailty & aging·2024
Same author

Evidence-based decision-making in a climate of political expediency: insights from local government.

Perspectives in public health·2024
Same author

The impact of patient-reported frailty on cardiovascular outcomes in elderly patients after non-ST-acute coronary syndrome.

International journal of cardiology·2024
Same author

Rare Variant of Lateral Medullary Syndrome; Opalski Syndrome with Cerebellar Infarction.

Irish medical journal·2023
Same journal

Age-associated impairment of humoral and cellular immune responses to SARS-CoV-2 in a large community cohort with hybrid immunity.

The Journal of infection·2026
Same journal

Genomic characterization of a large-scale chikungunya outbreak in China.

The Journal of infection·2026
Same journal

Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.

The Journal of infection·2026
Same journal

Multi-strain Clostridioides difficile infection: Increased detection and clinical implications.

The Journal of infection·2026
Same journal

A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment.

The Journal of infection·2026
Same journal

Defining the threshold duration of candidemia associated with poor outcomes: Redefining persistent candidemia.

The Journal of infection·2026
See all related articles

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Antimicrobial Stewardship

Background:

  • Pharmacoeconomics is increasingly utilized in strategic therapeutic decision-making.
  • Antimicrobial costs encompass acquisition, preparation, administration, monitoring, adverse effects, resistance, therapeutic failures, and length of stay.
  • Hospital Drug and Therapeutics Committees often prioritize acquisition costs, despite antimicrobials representing a small fraction of total revenue.

Purpose of the Study:

  • To highlight the comprehensive cost factors in antimicrobial pharmacoeconomics.
  • To emphasize the need to consider less tangible costs like staff time and resistance in decision-making.
  • To advocate for improved education and mechanisms to realize pharmacoeconomic savings.

Main Methods:

Related Experiment Videos

  • Analysis of various cost components associated with antimicrobial use.
  • Evaluation of decision-making criteria within hospital committees.
  • Discussion of challenges in quantifying resistance and risk management costs.

    • Main Results:

    • Acquisition costs and consumables are immediate financial considerations.
    • Staff time and monitoring costs are less tangible but significant.
    • Quantifying microbial resistance and risk management is challenging yet crucial for strategic decisions.

    Conclusions:

    • Strategic antimicrobial decision-making requires a holistic view of all associated costs.
    • Effective pharmacoeconomic implementation necessitates addressing budget handling for staff time and monitoring.
    • Educational initiatives and systemic changes are needed to fully leverage pharmacoeconomics for antimicrobial stewardship.